Executive Profiles

Executive Roundtable

Leadership

Press Releases

Corporate Communications

Healthcare Access

Patient Education

Telehealth

Direct-to-Consumer

Funding

Partnerships

Emerging Biopharma

Finance

Industry Trends

IR Licensing and Partnerships

Patient Access

Pricing

Strategy

Market Access

Clinical Data

Patient Advocacy

Pharmacovigilance

Medical Affairs

R&D/Clinical Trials

Supply Chain

Sustainability

Technology

Operations

DE&I

Patient Engagement

Global

Legal

Regulatory

Campaigns

DTC Marketing

Medical Education

Sales & Marketing

News

Pharma Pulse

Academy

Multimedia

Editorial Podcasts

Editorial Videos

Profiles in Medicine

Conferences

Conference Coverage

Conference Listing

Publications

Pharmaceutical Executive

Partner Perspectives

Resources

Content Engagement Hubs

E-Books

Events

Webcasts

Whitepapers

Subscribe

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

About

Advertise

Contact Us

Editorial Board

Editorial Submission Guidelines

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

LinkedIN

Instagram

Facebook

Threads

Bluesky

Spotlight

Pharmaceutical Executive APEX Awards 

Latest Executive Roundtables

Topic

Sales and Marketing

1rem

Articles

The commercial and social value of non-financial performance.

Biopharma Sustainability Considered Essential

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

AI: Hungry for Power

JAMA study finds that redispensing oral anticancer drugs reduces approximately two-thirds of medication waste as healthcare stakeholders seek more sustainable practices.

Study: Redispensing Unused Medication Greatly Reduces Waste in Shift Toward Sustainability

A C-suite Q&A with Cristina Ortega Duran, President of Evinova.

What is the Transformation Playbook for Moving From Digital Pilot to a Truly Scaled Production Solution? 

Recognition of the business case for ESG in pharma is soaring.

Sustainability and Progress Continue to Make Headlines in 2024

Emerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.

How Digital Twins Drive Sustainability in Clinical Supply Planning

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward.

Long-Term Sustainability for Diverse Trial Initiatives

 video interview, LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses strategies to address underrepresentation in clinical trials, particularly in phase III psoriasis trials. Robinson also discusses the company's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to improve engagement, address operational barriers, and prioritize sites with diverse patient demographics. Takeda has also enhanced investigator diversity through multilingual toolkits and educational sessions, and aims to expand these efforts globally by adapting strategies to regional needs.

Pharmaceutical Executive: What are the long-term sustainability plans for these initiatives? How will Takeda ensure that diversity and inclusion remain a priority in its clinical trials moving forward?


We talked a little bit about our US efforts, but we're also intending to expand globally and this trial is included with that. We're also making sure that, region by region, we're adapting the trial to what is best for that region and the perspective that each of those patient populations or communities may bring. We try to get to the community before they've thought of a clinical trial so that they're empowered with that information. Region by region, that may differ. I'm really looking forward to the learnings that we'll get as we're connecting in different areas of the world around clinical research, and how we can make it a reality to connect.

As we may see a change, we are committed to patients, or what I like to call, PTRB: patient, trust, reputation, business. That is our corporate philosophy and those are always our four priorities when we are looking at developing a treatment. When we think about the reflection of disease in our clinical trials and making sure that it accurately reflects the patient population, it really becomes about what's best for patients and making sure that we have the best scientific research to do that.

Videos

Sustainability

Latest News

More News